|
|||||
|
|
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke |
|
| Authors: | Fang Liu Udaya S Tantry Paul A Gurbel |
| Affiliation: | 1. Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W. Belvedere Ave, Baltimore, MD 21215, USA +1 410 601 9600;2. +1 410 601 9601;3. pgurbel@lifebridgehealth.org;4. Beijing Hospital, Department of Neurology, Beijing, China |
| Abstract: | Introduction: Ischemic stroke (IS) is a major cause of death and disability worldwide. The P2Y12 receptor plays a critical role in the formation of a stable thrombus leading to ischemic complications. Therefore, P2Y12 receptor inhibitors constitute a major antiplatelet strategy in the secondary prevention of IS. Areas covered: We searched articles about P2Y12 receptor inhibitors and stroke in PubMed published until December 2014. This is a comprehensive review of the role of P2Y12 receptor inhibitors alone and in combination with aspirin in the secondary prevention of noncardioembolic stroke. Expert opinion: The potential benefit of more potent antiplatelet therapy for secondary stroke prevention must be weighed against the risk of bleeding in patients with IS. Short-term (≤ 3 months) dual antiplatelet therapy with clopidogrel and aspirin that is initiated early after IS or transient ischemic attack due to large artery atherosclerosis appears most efficient. |
| Keywords: | clopidogrel P2Y12 receptor inhibitor prasugrel stroke ticagrelor ticlopidine |